Apollon Wealth Management LLC Sells 2,027 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Apollon Wealth Management LLC lessened its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 27.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,330 shares of the company's stock after selling 2,027 shares during the period. Apollon Wealth Management LLC's holdings in IDEXX Laboratories were worth $2,204,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in IDXX. Chicago Partners Investment Group LLC grew its holdings in shares of IDEXX Laboratories by 16.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock valued at $340,000 after acquiring an additional 96 shares in the last quarter. National Pension Service grew its holdings in shares of IDEXX Laboratories by 7.3% in the 3rd quarter. National Pension Service now owns 185,972 shares of the company's stock valued at $93,957,000 after acquiring an additional 12,647 shares in the last quarter. Insight Wealth Strategies LLC grew its holdings in shares of IDEXX Laboratories by 230.5% in the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock valued at $4,174,000 after acquiring an additional 7,041 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of IDEXX Laboratories by 17,238.5% in the 3rd quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock valued at $1,139,000 after acquiring an additional 2,241 shares in the last quarter. Finally, Quest Partners LLC grew its holdings in shares of IDEXX Laboratories by 4,059.4% in the 3rd quarter. Quest Partners LLC now owns 2,870 shares of the company's stock valued at $1,450,000 after acquiring an additional 2,801 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Sophie V. Vandebroek sold 344 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now owns 905 shares of the company's stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 13,330 shares of company stock worth $6,161,276 over the last three months. Insiders own 2.11% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on IDXX shares. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Wednesday, February 5th. Morgan Stanley reduced their price target on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. Leerink Partners started coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an "outperform" rating and a $500.00 price target for the company. Finally, Barclays lifted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $533.75.

IDEXX Laboratories Stock Performance

IDXX stock traded up $2.41 during mid-day trading on Thursday, hitting $459.76. 601,058 shares of the company were exchanged, compared to its average volume of 718,152. The business has a 50 day simple moving average of $430.12 and a 200-day simple moving average of $453.26. The company has a current ratio of 1.31, a quick ratio of 1.03 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $37.65 billion, a PE ratio of 43.09, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.